EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Providing holistic care for patients with m etabolic dysfunction‐associated steatotic liver disease/metabolic dysfunction‐associated steatohepatitis: Key aspects of clinical assessment and how to develop individualised care plans for surveillance and interventions

Lanlan Chen iD, Paul Horn, Frank Tacke

Diabetes, Obesity and Metabolism · 2026-04 · 28 (S2) · 46-62

DOI: 10.1111/dom.70545 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 11.02.2026. Verfasst von Lanlan Chen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology and Gastroenterology, Campus Virchow-Klinikum (CVK) and Campus Charité Mitte (CCM), Charité - Universitätsmedizin Berlin, Be…. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Holistic Health, Fatty Liver, Metabolic Diseases. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Germany's Excellence Strategy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction‐associated steatotic liver disease (MASLD), characterised by hepatic steatosis and metabolic dysfunction (i.e., obesity, type 2 diabetes, dyslipidaemia, and hypertension), is affecting over 30% of the adult population worldwide. It can progress to metabolic dysfunction‐associated steatohepatitis (MASH) and fibrosis, cirrhosis and even hepatocellular carcinoma. However, most patients with non‐cirrhotic MASLD die from extrahepatic causes, particularly cardiovascular disease and non‐hepatic cancers, underscoring the need for a holistic approach to surveillance and treatment. Emerging research on MASLD has revealed a substantial heterogeneity in the MASLD population, driven by sex‐specific factors, genetic susceptibility, cardiometabolic risk profile, lifestyle and socio‐economic determinants, highlighting the necessity of individualised and holistic management of MASLD patients. Although lifestyle intervention remains the cornerstone of MASLD, the pharmacotherapeutic landscape is rapidly evolving, with resmetirom and semaglutide now approved for non‐cirrhotic MASH with moderate‐to‐advanced fibrosis. In addition, metabolic/bariatric surgery has proven to be a highly effective option for patients with MASH. Given its close association with cardiometabolic and malignant comorbidities, MASLD requires individualised, holistic management integrating hepatic and extrahepatic risks. Multiprofessional care, involving among others behavioural therapists, dieticians and physiotherapists, may improve outcomes of lifestyle interventions, particularly in high‐risk settings. A stepwise and integrated care model combining early case‐finding, risk stratification, and tailored lifestyle and pharmacological interventions is essential to address both hepatic and extrahepatic complications. This review summarises the current understanding of MASLD heterogeneity, clinical assessment, and therapeutic advances, and outlines principles for individualised and coordinated care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseHolistic HealthFatty LiverMetabolic DiseasesHumansPrecision MedicineDiabetes Mellitus, Type 2Patient Care PlanningBariatric SurgeryObesityLife Style

Stichwörter der Autor:innen

GLP‐1cardiovascular diseasediabetes complicationsfatty liver diseaseobesity careweight management

Autor:innen und Institutionen

  • Department of Hepatology and Gastroenterology, Campus Virchow-Klinikum (CVK) and Campus Charité Mitte (CCM), Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, the First Hospital of Jilin University, Changchun, China.
  • BIH Biomedical Innovation Academy, BIH Charité Digital Clinician Scientist Program, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.

ORCID-Profile: Lanlan Chen

Förderung

  • Deutsche Forschungsgemeinschaft
  • Germany's Excellence Strategy

Zitieren

APA

Chen, L., Horn, P., & Tacke, F. (2026). Providing holistic care for patients with m etabolic dysfunction‐associated steatotic liver disease/metabolic dysfunction‐associated steatohepatitis: Key aspects of clinical assessment and how to develop individualised care plans for surveillance and interventions. Diabetes, Obesity and Metabolism, 28(S2), 46-62. https://doi.org/10.1111/dom.70545

Vancouver

Chen L, Horn P, Tacke F. Providing holistic care for patients with m etabolic dysfunction‐associated steatotic liver disease/metabolic dysfunction‐associated steatohepatitis: Key aspects of clinical assessment and how to develop individualised care plans for surveillance and interventions. Diabetes, Obesity and Metabolism. 2026;28(S2):46-62. doi:10.1111/dom.70545

BibTeX
@article{Chen2026,
  author = {Chen, Lanlan and Horn, Paul and Tacke, Frank},
  title = {Providing holistic care for patients with m etabolic dysfunction‐associated steatotic liver disease/metabolic dysfunction‐associated steatohepatitis: Key aspects of clinical assessment and how to develop individualised care plans for surveillance and interventions},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {S2},
  pages = {46--62},
  doi = {10.1111/dom.70545}
}
Kostenlos starten →